Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Correspondence] Questions in the design of ANSWER – Authors’ reply

We thank Ian A Rowe and Richard Parker for their interest in our study and their comments.1 They point out that refractory ascites was an endpoint in the trial and that participants were censored with that event. Indeed, refractory ascites was a secondary endpoint, along with the occurrence of other complications of cirrhosis. However, patients developing refractory ascites were not censored and continued to be followed up. In fact, 12 cases of liver transplantation or transjugular intrahepatic porto-systemic shunt (TIPS) insertion and 25 deaths (15 in the standard-treatment group and ten in the albumin group) were observed after onset of refractory ascites.